Although trastuzumab is predominantly employed post-operatively or in the treatment of metastatic HER-2-overexpressing breast cancer, clinicians worldwide have hypothesized that a trastuzumab-associated chemotherapeutic scheme may enhance the pCR of HER-2-overexpressing breast cancer patients by a large margin (28,29). The gene discussed is ERBB2; the disease is breast cancer.